Your session is about to expire
← Back to Search
Triple Therapy for Chronic Lymphocytic Leukemia
Study Summary
This trial is studying how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or Richter syndrome that has come back or does not respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My CLL has spread to my brain or its coverings.I do not have any untreated or uncontrolled infections.I haven't had any cancer except for certain types in the past 2 years.I have taken specific medications before.I have not had a stroke or brain bleed in the last 3 months.I haven't had major surgery or therapy in the last 4 weeks.I have not received any live vaccines recently.I have severe ongoing health or mental health issues.I still have side effects from previous cancer treatments.I have serious heart-related conditions.I have been diagnosed with CLL, SLL, or RT and have not received any treatment.I can take care of myself and am up and about more than half of my waking hours.My kidney and liver are working well.My blood pressure is not controlled by medication.I have received an organ transplant from another person.I have a history of lung conditions.I have hepatitis B, C, or HIV.I am 18 years old or older.My blood thinner medication dose has been stable.I have taken strong CYP3A inhibitors or inducers.I am currently taking high-dose steroids or medications that suppress my immune system.I am using effective birth control as a man with a partner who can become pregnant.I am not pregnant and agree to use birth control.I have a serious liver condition.
- Group 1: Cohort II (obinutuzumab, atezolizumab, venetoclax)
- Group 2: Cohort I (obinutuzumab, atezolizumab, venetoclax)
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are being accepted for this medical experiment?
"Affirmative, according to clinicaltrials.gov this research is currently enrolling participants. It was first listed on January 31st 2017 and recently updated on August 23rd 2022 with the aim of recruiting 65 people from a single site."
What therapeutic purposes is Atezolizumab typically employed for?
"Atezolizumab is routinely used to treat chronic lymphocytic leukemia (CLL) as well as pharmacotherapy, small cell lung cancer (SCLC), and malignant neoplasms."
Is this an unprecedented or untested clinical trial?
"Atezolizumab has been in circulation since 2008, when it was initially developed and sponsored by Hoffmann-La Roche. Following the Phase 1 trial involving 720 participants, Atezolizumab went on to receive its drug approval for Phase 2 trials. Presently there are 627 active clinical studies being conducted across 2090 cities and 75 countries concerning this medication's efficacy."
Has Atezolizumab attained regulatory endorsement from the FDA?
"The safety of Atezolizumab was assigned a rating of 2, as evidence from Phase 2 clinical trials supports its security but there is still no data to verify its efficacy."
Have any other investigations been conducted with Atezolizumab?
"Presently, 627 trials are underway for Atezolizumab. Out of those studies, 105 have completed Phase 3 and entered real-world testing. Initially based in Edmonton, Alberta, 26910 locations are now running clinical tests on this medication."
Is recruitment for this experiment still ongoing?
"Affirmative. The clinical trial is actively recruiting participants, as evidenced on the listings found on clincialtrials.gov. Initially posted in January of 2017 and revised August 23rd 2022, this research effort seeks 65 patients from one site for participation."
Share this study with friends
Copy Link
Messenger